Back Article

DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, et al. 2014. Cancer treatment and survivorship statistics, 2014. CA: A Cancer Journal for Clinicians 64(4):252−271

Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. 2014. Childhood and adolescent cancer statistics, 2014. CA: A Cancer Journal for Clinicians 64(2):83−103

Hu J, Hu K, Cheng Y. 2016. Tailoring the dendrimer core for efficient gene delivery. Acta Biomaterialia 35:1−11

Sanchez-Garcia L, Martín L, Mangues R, Ferrer-Miralles N, Vázquez E, et al. 2016. Recombinant pharmaceuticals from microbial cells: a 2015 update. Microbial Cell Factories 15(1):33

Chudy M, Tokarska K, Jastrzębska E, Bułka M, Drozdek S, et al. 2018. Lab-on-a-chip systems for photodynamic therapy investigations. Biosensors and Bioelectronics 101:37−51

Mitragotri S, Burke PA, Langer R. 2014. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nature Reviews Drug Discovery 13(9):655−672

Liu X, Wu F, Ji Y, Yin L. 2019. Recent advances in anti-cancer protein/peptide delivery. Bioconjugate Chemistry 30(2):305−324

Sandbhor P, Palkar P, Bhat S, John G, Goda JS. 2024. Nanomedicine as a multimodal therapeutic paradigm against cancer: on the way forward in advancing precision therapy. Nanoscale 16(13):6330−6364

Zheng C, Li M, Ding J. 2021. Challenges and opportunities of nanomedicines in clinical translation. BIO Integration 2(2):57−60

Dadwal A, Baldi A, Kumar Narang R. 2018. Nanoparticles as carriers for drug delivery in cancer. Artificial Cells, Nanomedicine, and Biotechnology 46(sup2):295−305

Nasrollahzadeh M, Sajadi SM, Sajjadi M, Issaabadi Z. 2019. An introduction to green nanotechnology. In Interface Science and Technology. Volume 28. Amsterdam: Elsevier. pp. 1−27 doi: 10.1016/b978-0-12-813586-0.00001-8

Emerich DF, Thanos CG. 2003. Nanotechnology and medicine. Expert Opinion on Biological Therapy 3(4):655−663

Alexis F, Rhee JW, Richie JP, Radovic-Moreno AF, Langer R, et al. 2008. New frontiers in nanotechnology for cancer treatment. Urologic Oncology: Seminars and Original Investigations 26(1):74−85

Moghimi SM, Hunter AC, Murray JC. 2005. Nanomedicine: current status and future prospects. The FASEB Journal 19(3):311−330

Langer R. 1998. Drug delivery and targeting. Nature 392:5−10

Farokhzad OC, Langer R. 2009. Impact of nanotechnology on drug delivery. ACS Nano 3(1):16−20

Park K. 2016. Drug delivery research: the invention cycle. Molecular Pharmaceutics 13(7):2143−2147

Park K. 2013. Facing the truth about nanotechnology in drug delivery. ACS Nano 7(9):7442−7447

Gowda R. 2013. Use of nanotechnology to develop multi-drug inhibitors for cancer therapy. Journal of Nanomedicine & Nanotechnology 4(6):184

Yu M, Wu J, Shi J, Farokhzad OC. 2016. Nanotechnology for protein delivery: overview and perspectives. Journal of Controlled Release 240:24−37

Misra R, Acharya S, Sahoo SK. 2010. Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Discovery Today 15(19−20):842−850

Sun D, Sun X, Zhang X, Wu J, Shi X, et al. 2024. Emerging chemodynamic nanotherapeutics for cancer treatment. Advanced Healthcare Materials 13(22):e2400809

Singh R, Dheek M, Chauhan SB, Singh I. 2025. Nanotherapeutics in cancer-associated infections. In Applications of Nanotherapeutics and Nanotheranostics in Managing Infectious Diseases. Amsterdam: Elsevie. pp. 553−581 doi: 10.1016/b978-0-443-28836-4.00023-8

Bae Y, Jang WD, Nishiyama N, Fukushima S, Kataoka K. 2005. Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery. Molecular BioSystems 1(3):242−250

Nasongkla N, Bey E, Ren J, Ai H, Khemtong C, et al. 2006. Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Letters 6(11):2427−2430

Shen H, Shi S, Zhang Z, Gong T, Sun X. 2015. Coating solid lipid nanoparticles with hyaluronic acid enhances antitumor activity against melanoma stem-like cells. Theranostics 5(7):755−771

Bassas-Galia M, Follonier S, Pusnik M, Zinn M. 2017. Natural polymers: a source of inspiration. In Bioresorbable Polymers for Biomedical Applications. Amsterdam: Elsevier. pp. 31−64 doi: 10.1016/b978-0-08-100262-9.00002-1

Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, et al. 2006. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Research 66(13):6732−6740

Ali Khawar I, Kim JH, Kuh HJ. 2015. Improving drug delivery to solid tumors: priming the tumor microenvironment. Journal of Controlled Release 201:78−89

Garg P, Pareek S, Kulkarni P, Salgia R, Singhal SS. 2024. Nanoengineering solutions for cancer therapy: bridging the gap between clinical practice and translational research. Journal of Clinical Medicine 13(12):3466

Raj M, Chopra D, Kumar Upadhyay S, Singh M, Sharma AK. 2024. Recent advances in cancer therapy: drug delivery, nanotherapeutics, and future perspectives. Anticancer Therapeutics: Bionanotechnology, Nanomedicine and Phytochemicals. Germany: De Gruyter. pp. 273−316 doi: 10.1515/9783111349541-009

Wang X, Yang L, Chen Z, Shin DM. 2008. Application of nanotechnology in cancer therapy and imaging. CA: A Cancer Journal for Clinicians 58(2):97−110

Forte E, Fiorenza D, Torino E, Costagliola di Polidoro A, Cavaliere C, et al. 2020. Radiolabeled PET/MRI nanoparticles for tumor imaging. Journal of Clinical Medicine 9(1):89

Lin PC, Lin S, Wang PC, Sridhar R. 2014. Techniques for physicochemical characterization of nanomaterials. Biotechnology Advances 32(4):711−726

Rodrigues T, Reker D, Schneider P, Schneider G. 2016. Counting on natural products for drug design. Nature Chemistry 8(6):531−541

Bukhari B, Naveed M, Makhdoom SI, Jabeen K, Asif MF, et al. 2021. A comparison between organic and inorganic nanoparticles: prime nanoparticles for tumor curation. Nano 16(13):2130011

Bodunde OP, Ikumapayi OM, Akinlabi ET, Oladapo BI, Adeoye AOM, et al. 2021. A futuristic insight into a "nano-doctor": a clinical review on medical diagnosis and devices using nanotechnology. Materials Today: Proceedings 44:1144−1153

Greene MK, Johnston MC, Scott CJ. 2021. Nanomedicine in pancreatic cancer: current status and future opportunities for overcoming therapy resistance. Cancers 13(24):6175

Park SH, Oh SG, Mun JY, Han SS. 2006. Loading of gold nanoparticles inside the DPPC bilayers of liposome and their effects on membrane fluidities. Colloids and Surfaces B: Biointerfaces 48(2):112−118

Hua S, Wu SY. 2013. The use of lipid-based nanocarriers for targeted pain therapies. Frontiers in Pharmacology 4:143

Kim CH, Lee SG, Kang MJ, Lee S, Choi YW. 2017. Surface modification of lipid-based nanocarriers for cancer cell-specific drug targeting. Journal of Pharmaceutical Investigation 47(3):203−227

Iyer AK, Su Y, Feng J, Lan X, Zhu X, et al. 2011. The effect of internalizing human single chain antibody fragment on liposome targeting to epithelioid and sarcomatoid mesothelioma. Biomaterials 32:2605−2613

Liu Y, Quan X, Li J, Huo J, Li X, et al. 2023. Liposomes embedded with PEGylated iron oxide nanoparticles enable ferroptosis and combination therapy in cancer. National Science Review 10:nwac167

Marasini N, Ghaffar KA, Skwarczynski M, Toth I. 2017. Liposomes as a vaccine delivery system. In Micro and Nanotechnology in Vaccine Development. Amsterdam: Elsevier. pp. 221−239 doi: 10.1016/b978-0-323-39981-4.00012-9

Zylberberg C, Matosevic S. 2016. Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape. Drug Delivery 23(9):3319−3329

Wang X, Liu X, Li Y, Wang P, Feng X, et al. 2017. Sensitivity to antitubulin chemotherapeutics is potentiated by a photoactivable nanoliposome. Biomaterials 141:50−62

Han B, Yang Y, Chen J, Tang H, Sun Y, et al. 2020. Preparation, characterization, and pharmacokinetic study of a novel long-acting targeted paclitaxel liposome with antitumor activity. International Journal of Nanomedicine 15:553−571

O'Brien MER, Wigler N, Inbar M, Rosso R, Grischke E, et al. 2004. Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer. Annals of Oncology 15(3):440−449

Geisberg CA, Sawyer DB. 2010. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Current Hypertension Reports 12(6):404−410

Zocchi MR, Tosetti F, Benelli R, Poggi A. 2020. Cancer nanomedicine special issue review anticancer drug delivery with nanoparticles: extracellular vesicles or synthetic nanobeads as therapeutic tools for conventional treatment or immunotherapy. Cancers 12(7):1886

Vader P, Mol EA, Pasterkamp G, Schiffelers RM. 2016. Extracellular vesicles for drug delivery. Advanced Drug Delivery Reviews 106:148−156

Antes TJ, Middleton RC, Luther KM, Ijichi T, Peck KA, et al. 2018. Targeting extracellular vesicles to injured tissue using membrane cloaking and surface display. Journal of Nanobiotechnology 16(1):61

Witwer KW, Wolfram J. 2021. Extracellular vesicles versus synthetic nanoparticles for drug delivery. Nature Reviews Materials 6(2):103−106

Jeppesen DK, Zhang Q, Franklin JL, Coffey RJ. 2023. Extracellular vesicles and nanoparticles: emerging complexities. Trends in Cell Biology 33(8):667−681

Chiang CL, Ma Y, Hou YC, Pan J, Chen SY, et al. 2023. Dual targeted extracellular vesicles regulate oncogenic genes in advanced pancreatic cancer. Nature Communications 14:6692

Masood F, Chen P, Yasin T, Fatima N, Hasan F, et al. 2013. Encapsulation of Ellipticine in poly-(3-hydroxybutyrate-co-3-hydroxyvalerate) based nanoparticles and its in vitro application. Materials Science and Engineering: C 33(3):1054−1060

Ganta S, Talekar M, Singh A, Coleman TP, Amiji MM. 2014. Nanoemulsions in translational research—opportunities and challenges in targeted cancer therapy. AAPS PharmSciTech 15(3):694−708

Kim B, Pena CD, Auguste DT. 2019. Targeted lipid nanoemulsions encapsulating epigenetic drugs exhibit selective cytotoxicity on CDH1⁻/FOXM1⁺ triple negative breast cancer cells. Molecular Pharmaceutics 16(5):1813−1826

Mahato R. 2017. Nanoemulsion as targeted drug delivery system for cancer therapeutics. Journal of Pharmaceutical Sciences and Pharmacology 3(2):83−97

Ganta S, Devalapally H, Shahiwala A, Amiji M. 2008. A review of stimuli-responsive nanocarriers for drug and gene delivery. Journal of Controlled Release 126(3):187−204

Zahr AS, Davis CA, Pishko MV. 2006. Macrophage uptake of core–shell nanoparticles surface modified with poly(ethylene glycol). Langmuir 22(19):8178−8185

Stolnik S, Daudali B, Arien A, Whetstone J, Heald CR, et al. 2001. The effect of surface coverage and conformation of poly(ethylene oxide) (PEO) chains of poloxamer 407 on the biological fate of model colloidal drug carriers. Biochimica et Biophysica Acta (BBA) - Biomembranes 1514(2):261−279

Alvarez-Lorenzo C. 2010. Poloxamine-based nanomaterials for drug delivery. Frontiers in Bioscience E 2(2):424−440

Ganta S, Deshpande D, Korde A, Amiji M. 2010. A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers. Molecular Membrane Biology 27(7):260−273

Maranhao JA, Valduga CJ, Tavares ER, Kretzer IF, Maria AD, et al. 2011. Novel formulation of a methotrexate derivative with a lipid nanoemulsion. International Journal of Nanomedicine 6:2285−2295

Winter E, Pizzol CD, Locatelli C, Silva AH, Conte A, et al. 2014. In vitro and in vivo effects of free and chalcones-loaded nanoemulsions: insights and challenges in targeted cancer chemotherapies. International Journal of Environmental Research and Public Health 11(10):10016−10035

Mein JR, Lian F, Wang XD. 2008. Biological activity of lycopene metabolites: implications for cancer prevention. Nutrition Reviews 66(12):667−683

Chen YJ, Inbaraj BS, Pu YS, Chen BH. 2014. Development of lycopene micelle and lycopene chylomicron and a comparison of bioavailability. Nanotechnology 25(15):155102

Lu W, Zhang G, Zhang R, Flores LG II, Huang Q, et al. 2010. Tumor site–specific silencing of NF-κB p65 by targeted hollow gold nanosphere–mediated photothermal transfection. Cancer Research 70(8):3177−3188

Periasamy VS, Athinarayanan J, Alshatwi AA. 2016. Anticancer activity of an ultrasonic nanoemulsion formulation of Nigella sativa L. essential oil on human breast cancer cells. Ultrasonics Sonochemistry 31:449−455

Migotto A, Carvalho VFM, Salata GC, da Silva FWM, Yan CYI, et al. 2018. Multifunctional nanoemulsions for intraductal delivery as a new platform for local treatment of breast cancer. Drug Delivery 25(1):654−667

Natesan S, Sugumaran A, Ponnusamy C, Thiagarajan V, Palanichamy R, et al. 2017. Chitosan stabilized camptothecin nanoemulsions: development, evaluation and biodistribution in preclinical breast cancer animal mode. International Journal of Biological Macromolecules 104:1846−1852

Liang S, Sun C, Yang P, Ma PA, Huang S, et al. 2020. Core-shell structured upconversion nanocrystal-dendrimer composite as a carrier for mitochondria targeting and catalase enhanced anti-cancer photodynamic therapy. Biomaterials 240:119850

Duan Y, Dhar A, Patel C, Khimani M, Neogi S, et al. 2020. A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems. RSC Advances 10(45):26777−26791

Hou D, Xie C, Huang K, Zhu C. 2003. The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials 24(10):1781−1785

Uner M, Yener G. 2007. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. International Journal of Nanomedicine 2(2):289−300

Akanda M, Getti G, Nandi U, Mithu MS, Douroumis D. 2021. Bioconjugated solid lipid nanoparticles (SLNs) for targeted prostate cancer therapy. International Journal of Pharmaceutics 599:120416

Jiang Y, Huo S, Hardie J, Liang XJ, Rotello VM. 2016. Progress and perspective of inorganic nanoparticle-based siRNA delivery systems. Expert Opinion on Drug Delivery 13(4):547−559

Han G, Ghosh P, Rotello VM. 2007. Functionalized gold nanoparticles for drug delivery. Nanomedicine 2(1):113−123

Samadian H, Hosseini-Nami S, Kamrava SK, Ghaznavi H, Shakeri-Zadeh A. 2016. Folate-conjugated gold nanoparticle as a new nanoplatform for targeted cancer therapy. Journal of Cancer Research and Clinical Oncology 142(11):2217−2229

Tang Y, Liang J, Wu A, Chen Y, Zhao P, et al. 2017. Co-delivery of trichosanthin and albendazole by nano-self-assembly for overcoming tumor multidrug-resistance and metastasis. ACS Applied Materials & Interfaces 9(32):26648−26664

Xu H, Wang Y, Pei Z, Ji W, Pei Y. 2019. NIRF turn-on nanoparticles based on the tumor microenvironment for monitoring intracellular protein delivery. Chemical Communications 55(99):14930−14933

Farzin A, Etesami SA, Quint J, Memic A, Tamayol A. 2020. Magnetic nanoparticles in cancer therapy and diagnosis. Advanced Healthcare Materials 9(9):1901058

Knežević NŽ, Gadjanski I, Durand JO. 2019. Magnetic nanoarchitectures for cancer sensing, imaging and therapy. Journal of Materials Chemistry B 7(1):9−23

Santhosh PB, Ulrih NP. 2013. Multifunctional superparamagnetic iron oxide nanoparticles: promising tools in cancer theranostics. Cancer Letters 336(1):8−17

Lim SY, Shen W, Gao Z. 2015. Carbon quantum dots and their applications. Chemical Society Reviews 44(1):362−381

Desmond LJ, Phan AN, Gentile P. 2021. Critical overview on the green synthesis of carbon quantum dots and their application for cancer therapy. Environmental Science: Nano 8(4):848−862

Fam SY, Chee CF, Yong CY, Ho KL, Mariatulqabtiah AR, et al. 2020. Stealth coating of nanoparticles in drug-delivery systems. Nanomaterials 10(4):787

Liu Z, Tabakman S, Welsher K, Dai H. 2009. Carbon nanotubes in biology and medicine: in vitro and in vivo detection, imaging and drug delivery. Nano Research 2(2):85−120

Orive G, Gascón AR, Hernández RM, Domínguez-Gil A, Pedraz JL. 2004. Techniques: new approaches to the delivery of biopharmaceuticals. Trends in Pharmacological Sciences 25(7):382−387

Zafar Razzacki S, Thwar PK, Yang M, Ugaz VM, Burns MA. 2004. Integrated microsystems for controlled drug delivery. Advanced Drug Delivery Reviews 56(2):185−198

Arayne MS, Sultana N, Qureshi F. 2007. Review: nanoparticles in delivery of cardiovascular drugs. Pakistan Journal of Pharmaceutical Sciences 20:315−325

Patra JK, Baek KH. 2014. Green nanobiotechnology: factors affecting synthesis and characterization techniques. Journal of Nanomaterials 2014:417305

Joseph RR, Venkatraman SS. 2017. Drug delivery to the eye: what benefits do nanocarriers offer? Nanomedicine 12(6):683−702

He H, Chen Y, Li Y, Song Z, Zhong Y, et al. 2018. Effective and selective anti-cancer protein delivery via all-functions-in-one nanocarriers coupled with visible light-responsive, reversible protein engineering. Advanced Functional Materials 28(14):1706710

Blanco E, Shen H, Ferrari M. 2015. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nature Biotechnology 33(9):941−951

Esmaeili J, Jalise SZ, Tebyani A. 2025. The role of functional groups in tissue adhesives: a mini-review. Regenerative Engineering and Translational Medicine

Habibi S, Bahramian S, Zare Jalise S, Mehri S, Ababzadeh S, et al. 2025. Novel strategies in breast cancer management: from treatment to long-term remission. Critical Reviews in Oncology/Hematology 211:104715

Zare Jalise S, Kheirkhah AH, Poondla N, Sardarabadi H, Sheykhhasan M. 2026. Nanotherapeutics for colorectal cancers using nanobiomaterials. In Current Applications of Nanobiomaterials, eds Arunachalam K, Anand K, Kumar SSD, Mohandoss S, Prasad R, et al. Volume 2. Cham: Springer. pp. 1−40 doi: 10.1007/978-3-032-08576-4_1

Huskić I, Pekov IV, Krivovichev SV, Friščić T. 2016. Minerals with metal-organic framework structures. Science Advances 2(8):e1600621

González-Toro DC, Ryu JH, Chacko RT, Zhuang J, Thayumanavan S. 2012. Concurrent binding and delivery of proteins and lipophilic small molecules using polymeric nanogels. Journal of the American Chemical Society 134(16):6964−6967

Zhang XQ, Xu X, Bertrand N, Pridgen E, Swami A, et al. 2012. Interactions of nanomaterials and biological systems: implications to personalized nanomedicine. Advanced Drug Delivery Reviews 64:1363−1384

Liu S. 2012. Epigenetics advancing personalized nanomedicine in cancer therapy. Advanced Drug Delivery Reviews 64(13):1532−1543

Deng S, Gigliobianco MR, Censi R, Di Martino P. 2020. Polymeric nanocapsules as nanotechnological alternative for drug delivery system: current status, challenges and opportunities. Nanomaterials 10(5):847

Khalid AD, Ur-Rehman N, Tariq GH, Ullah S, Buzdar SA, et al. 2023. Functional bioinspired nanocomposites for anticancer activity with generation of reactive oxygen species. Chemosphere 310:136885

Pei Y, Li M, Hou Y, Hu Y, Chu G, et al. 2018. An autonomous tumor-targeted nanoprodrug for reactive oxygen species-activatable dual-cytochrome c/doxorubicin antitumor therapy. Nanoscale 10:11418−11429

Kwon S, Ko H, You DG, Kataoka K, Park JH. 2019. Nanomedicines for reactive oxygen species mediated approach: an emerging paradigm for cancer treatment. Accounts of Chemical Research 52(7):1771−1782

Ramesh R, Amreddy N, Muralidharan R, Babu A, Mehta M, et al. 2015. Tumor-targeted and pH-controlled delivery of doxorubicin using gold nanorods for lung cancer therapy. International Journal of Nanomedicine 10:6773−6788

Roovers RC, Laeremans T, Huang L, De Taeye S, Verkleij AJ, et al. 2007. Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies. Cancer Immunology, Immunotherapy 56(3):303−317

Reck M, Kranich AL, Steinbach AK, Gatzemeier U. 2005. Neue molekulare therapien beim nichtkleinzelligen lungenkarzinom am beispiel der EGFR/HER1-Inhibition. EGFR/HER1 inhibition: an example of new targeted therapies in non-small cell lung cancer. Medizinische Klinik 100(12):785−793

Dienst A, Grunow A, Unruh M, Rabausch B, Nör JE, et al. 2005. Specific occlusion of murine and human tumor vasculature by VCAM-1–targeted recombinant fusion proteins. JNCI: Journal of the National Cancer Institute 97(10):733−747

Litman T, Brangi M, Hudson E, Fetsch P, Abati A, et al. 2000. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). Journal of Cell Science 113(11):2011−2021

Gabizon A, Horowitz AT, Goren D, Tzemach D, Mandelbaum-Shavit F, et al. 1999. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjugate Chemistry 10(2):289−298

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. 2000. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. Journal of Controlled Release 65(1−2):271−284

Jhaveri AM, Torchilin VP. 2014. Multifunctional polymeric micelles for delivery of drugs and siRNA. Frontiers in Pharmacology 5:77

Carmeliet P, Jain RK. 2000. Angiogenesis in cancer and other diseases. Nature 407(6801):249−257

Maeda H. 2001. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Advances in Enzyme Regulation 41(1):189−207

Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, et al. 2006. Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Annals of Oncology 17(8):1263−1268

Zhu S, Qian L, Hong M, Zhang L, Pei Y, et al. 2011. RGD-modified PEG-PAMAM-DOX conjugate: in vitro and in vivo targeting to both tumor neovascular endothelial cells and tumor cells. Advanced Materials 23(12):H84−H89

Chen Z. 2010. Small-molecule delivery by nanoparticles for anticancer therapy. Trends in Molecular Medicine 16(12):594−602

Cirillo G, Vittorio O, Kunhardt D, Valli E, Voli F, et al. 2019. Combining carbon nanotubes and chitosan for the vectorization of methotrexate to lung cancer cells. Materials 12(18):2889

Arvizo RR, Rana S, Miranda OR, Bhattacharya R, Rotello VM, et al. 2011. Mechanism of anti-angiogenic property of gold nanoparticles: role of nanoparticle size and surface charge. Nanomedicine: Nanotechnology, Biology and Medicine 7(5):580−587

Arvizo RR, Miranda OR, Thompson MA, Pabelick CM, Bhattacharya R, et al. 2010. Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano Letters 10(7):2543−2548

Gaster RS, Hall DA, Nielsen CH, Osterfeld SJ, Yu H, et al. 2009. Matrix-insensitive protein assays push the limits of biosensors in medicine. Nature Medicine 15(11):1327−1332

Galanzha EI, Shashkov EV, Kelly T, Kim JW, Yang L, et al. 2009. In vivo magnetic enrichment and multiplex photoacoustic detection of circulating tumour cells. Nature Nanotechnology 4(12):855−860

Rukh L, Ullah S, Naqvi MAQ, Ahmad I, Nawaz MY, et al. 2024. Cytotoxicity and genotoxicity induced by metal-based nanoparticles in humans and animals: nanoparticle toxicity. Letters in Animal Biology 4(2):01−10

Vanivska K, Dianová L, Halo M Jr, Štefunková N, Lenický M, et al. 2024. Toxicity of nanoparticles on animal and human organism: cell response. Journal of Microbiology, Biotechnology and Food Sciences 14:e10844

Bhardwaj LK, Rath P, Choudhury M. 2023. A comprehensive review on the classification, uses, sources of nanoparticles (NPs) and their toxicity on health. Aerosol Science and Engineering 7(1):69−86

Sengul AB, Asmatulu E. 2020. Toxicity of metal and metal oxide nanoparticles: a review. Environmental Chemistry Letters 18(5):1659−1683

Sharma N, Das Kurmi B, Singh D, Mehan S, Khanna K, et al. 2024. Nanoparticles toxicity: an overview of its mechanism and plausible mitigation strategies. Journal of Drug Targeting 32(5):457−469

Sharifi S, Behzadi S, Laurent S, Forrest ML, Stroeve P, et al. 2012. Toxicity of nanomaterials. Chemical Society Reviews 41(6):2323−2343

He W, Li X, Morsch M, Ismail M, Liu Y, et al. 2022. Brain-targeted codelivery of Bcl-2/Bcl-xl and Mcl-1 inhibitors by biomimetic nanoparticles for orthotopic glioblastoma therapy. ACS Nano 16(4):6293−6308

Fan L, Li F, Zhang H, Wang Y, Cheng C, et al. 2010. Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance. Biomaterials 31(21):5634−5642

Park SS, Lee DM, Lim JH, Lee D, Park SJ, et al. 2018. Pyrrolidine dithiocarbamate reverses Bcl-xL-mediated apoptotic resistance to doxorubicin by inducing paraptosis. Carcinogenesis 39(3):458−470

van Vlerken LE, Duan Z, Seiden MV, Amiji MM. 2007. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Research 67(10):4843−4850

Jabr-Milane LS, van Vlerken LE, Yadav S, Amiji MM. 2008. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treatment Reviews 34(7):592−602

Zhang C, Zhang X, Zhao W, Zeng C, Li W, et al. 2019. Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer. Nano Research 12(4):855−861

Babu A, Templeton AK, Munshi A, Ramesh R. 2013. Nanoparticle-based drug delivery for therapy of lung cancer: progress and challenges. Journal of Nanomaterials 2013(1):863951

Talekar M, Trivedi M, Shah P, Ouyang Q, Oka A, et al. 2016. Combination wt-p53 and microRNA-125b transfection in a genetically engineered lung cancer model using dual CD44/EGFR-targeting nanoparticles. Molecular Therapy 24(4):759−769

Dong Y, Liao H, Yu J, Fu H, Zhao D, et al. 2019. Incorporation of drug efflux inhibitor and chemotherapeutic agent into an inorganic/organic platform for the effective treatment of multidrug resistant breast cancer. Journal of Nanobiotechnology 17(1):125

Beh CW, Seow WY, Wang Y, Zhang Y, Ong ZY, et al. 2009. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug. Biomacromolecules 10(1):41−48

Zhao Y, Huan ML, Liu M, Cheng Y, Sun Y, et al. 2016. Doxorubicin and resveratrol co-delivery nanoparticle to overcome doxorubicin resistance. Scientific Reports 6:35267

Jurczyk M, Kasperczyk J, Wrześniok D, Beberok A, Jelonek K. 2022. Nanoparticles loaded with docetaxel and resveratrol as an advanced tool for cancer therapy. Biomedicines 10(5):1187

Pinzon-Daza M, Campia I, Kopecka J, Garzon R, Ghigo D, et al. 2013. Nanoparticle- and liposome-carried drugs: new strategies for active targeting and drug delivery across blood-brain barrier. Current Drug Metabolism 14(6):625−640

Jurczyk M, Jelonek K, Musiał-Kulik M, Beberok A, Wrześniok D, et al. 2021. Single- versus dual-targeted nanoparticles with folic acid and biotin for anticancer drug delivery. Pharmaceutics 13(3):326

Li M, Wu Y, He C, Li X, Tao J, et al. 2023. Mitochondria-targeting small-molecule NIR-II fluorescent probes for imaging and treatment of tumor (adv. therap. 11/2023). Advanced Therapeutics 6(11):2370031

Al-Thani AN, Jan AG, Abbas M, Geetha M, Sadasivuni KK. 2024. Nanoparticles in cancer theragnostic and drug delivery: a comprehensive review. Life Sciences 352:122899

Prieložná J, Mikušová V, Mikuš P. 2024. Advances in the delivery of anticancer drugs by nanoparticles and chitosan-based nanoparticles. International Journal of Pharmaceutics: X 8:100281

Lin Y, Chen X, Wang K, Liang L, Zhang H. 2024. An overview of nanoparticle-based delivery platforms for mRNA vaccines for treating cancer. Vaccines 12(7):727

Desai N, Chavda V, Singh TRR, Thorat ND, Vora LK. 2024. Cancer nanovaccines: nanomaterials and clinical perspectives. Small 20(35):2401631

Baljon JJ, Kwiatkowski AJ, Pagendarm HM, Stone PT, Kumar A, et al. 2024. A cancer nanovaccine for co-delivery of peptide neoantigens and optimized combinations of STING and TLR4 agonists. ACS Nano 18(9):6845−6862

Kheirkhah AH, Habibi S, Yousefi MH, Mehri S, Ma B, et al. 2024. Finding potential targets in cell-based immunotherapy for handling the challenges of acute myeloid leukemia. Frontiers in Immunology 15:1460437

Guo Y, Hu P, Shi J. 2024. Nanomedicine remodels tumor microenvironment for solid tumor immunotherapy. Journal of the American Chemical Society 146(15):10217−10233

Liang R, Xie J, Li J, Wang K, Liu L, et al. 2017. Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response. Biomaterials 149:41−50

Wang Y, Li J, Nakahata S, Iha H. 2024. Complex role of regulatory T cells (tregs) in the tumor microenvironment: their molecular mechanisms and bidirectional effects on cancer progression. International Journal of Molecular Sciences 25(13):7346

Zhong SJ, Liu X, Kaneko T, Feng Y, Hovey O, et al. 2024. Peptide blockers of PD-1-PD-L1 interaction reinvigorate PD-1-suppressed T cells and curb tumor growth in mice. Cells 13(14):1193

Lang C, Lantos A, Megyesfalvi Z, Egger F, Hoda MA, et al. 2022. Clinical and prognostic implications of CD47 and PD-L1 expression in surgically resected small-cell lung cancer. ESMO Open 7(6):100631

Ma GL, Lin WF. 2023. Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy. Military Medical Research 10(1):20

Guo Y, Li Y, Zhang M, Ma R, Wang Y, et al. 2024. Polymeric nanocarrier via metabolism regulation mediates immunogenic cell death with spatiotemporal orchestration for cancer immunotherapy. Nature Communications 15:8586

Hiep Tran T, Thu Phuong Tran T. 2024. Current status of nanoparticle-mediated immunogenic cell death in cancer immunotherapy. International Immunopharmacology 142:113085

Lei J, Qi S, Yu X, Gao X, Yang K, et al. 2024. Development of mannosylated lipid nanoparticles for mRNA cancer vaccine with high antigen presentation efficiency and immunomodulatory capability. Angewandte Chemie International Edition 63(13):e202318515

Banerjee K, Gautam SK, Kshirsagar P, Ross KA, Spagnol G, et al. 2019. Amphiphilic polyanhydride-based recombinant MUC4β-nanovaccine activates dendritic cells. Genes & Cancer 10(3−4):52−62

Korzun T, Moses AS, Jozic A, Grigoriev V, Newton S, et al. 2024. Lipid nanoparticles elicit reactogenicity and sickness behavior in mice via toll-like receptor 4 and myeloid differentiation protein 88 axis. ACS Nano 18(36):24842−24859

García-Fernández C, Virgilio T, Latino I, Guerra-Rebollo M, Gonzalez SF, et al. 2024. Stealth mRNA nanovaccines to control lymph node trafficking. Journal of Controlled Release 374:325−336

Cao Y, Long J, Sun H, Miao Y, Sang Y, et al. 2023. Dendritic cell-mimicking nanoparticles promote mRNA delivery to lymphoid organs. Advanced Science 10(33):2302423

Ni K, Luo T, Culbert A, Kaufmann M, Jiang X, et al. 2020. Nanoscale metal–organic framework co-delivers TLR-7 agonists and anti-CD47 antibodies to modulate macrophages and orchestrate cancer immunotherapy. Journal of the American Chemical Society 142:12579−12584

Lian S, Xie X, Lu Y, Jia L. 2019. Checkpoint CD47 function on tumor metastasis and immune therapy. Onco Targets and Therapy 12:9105−9114

Pham LM, Poudel K, Phung CD, Nguyen TT, Pandit M, et al. 2021. Preparation and evaluation of dabrafenib-loaded, CD47-conjugated human serum albumin-based nanoconstructs for chemoimmunomodulation. Colloids and Surfaces B: Biointerfaces 208:112093

Du C, Jiang J, Wan C, Pan G, Kong F, et al. 2022. AntiPD-L1 antibody conjugated Au-SPIOs nanoplatform for enhancing radiosensitivity and triggering anti-tumor immune response. Scientific Reports 12:19542

Alhallak K, Sun J, Wasden K, Guenthner N, O'Neal J, et al. 2021. Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy. Leukemia 35(8):2346−2357

Zhang Y, Zhang X, Gao Y, Liu S. 2025. Principles of lipid nanoparticle design for mRNA delivery. BMEMat 3(1):e12116

Zhu M, Wang R, Nie G. 2014. Applications of nanomaterials as vaccine adjuvants. Human Vaccines & Immunotherapeutics 10(9):2761−2774

Jacob EM, Huang J, Chen M. 2024. Lipid nanoparticle-based mRNA vaccines: a new frontier in precision oncology. Precision Clinical Medicine 7(3):pbae017

Zhang Z, Song P, Zhao Y, Li Y, Shao K, et al. 2024. Pharmacological effects and related mechanisms of Ganoderma Lucidum polysaccharides at the cellular level. Highlights in Science, Engineering and Technology 91:422−429

Lin Q, Zhou H, Zeng J, Zeng M, Kraithong S, et al. 2024. Bioactive polysaccharides mediate ferroptosis to modulate tumor immunotherapy. International Journal of Biological Macromolecules 279:135147

Xie J, Lin D, Li J, Zhou T, Lin S, et al. 2023. Effects of Ganoderma lucidum polysaccharide peptide ameliorating cyclophosphamide-induced immune dysfunctions based on metabolomics analysis. Frontiers in Nutrition 10:1179749

Murphy EJ, Fehrenbach GW, Abidin IZ, Buckley C, Montgomery T, et al. 2023. Polysaccharides—naturally occurring immune modulators. Polymers 15(10):2373

Xing J, Liu Z, Huang Y, Qin T, Bo R, et al. 2016. Lentinan-modified carbon nanotubes as an antigen delivery system modulate immune response in vitro and in vivo. ACS Applied Materials & Interfaces 8(30):19276−19283

Rai SN, Mishra D, Singh P, Singh MP, Vamanu E, et al. 2023. Biosynthesis and bioapplications of nanomaterials from mushroom products. Current Pharmaceutical Design 29(13):1002−1008

Wu Y, Liang X, Mao C, Jiang Y. 2023. The distinct properties of polysaccharide nanoparticles tune immune responses against mRNA antigen via stimulator of interferon genes-mediated autophagy and inflammasome. ACS Nano 17(21):21782−21798

Cordeiro AS, Farsakoglu Y, Crecente-Campo J, de la Fuente M, González SF, et al. 2021. Carboxymethyl-β-glucan/chitosan nanoparticles: new thermostable and efficient carriers for antigen delivery. Drug Delivery and Translational Research 11(4):1689−1702

Sanz-Ortega L, Rojas JM, Barber DF. 2020. Improving tumor retention of effector cells in adoptive cell transfer therapies by magnetic targeting. Pharmaceutics 12(9):812

Hawkins RE, Gilham DE, Debets R, Eshhar Z, Taylor N, et al. 2010. Development of adoptive cell therapy for cancer: a clinical perspective. Human Gene Therapy 21(6):665−672

Darcy PK, Neeson PJ. 2015. Adoptive immunotherapy: a new era for the treatment of cancer. Immunotherapy 7(5):469−471

Shrestha B, Zhang Y, Yu B, Li G, Boucher JC, et al. 2020. Generation of antitumor T cells for adoptive cell therapy with artificial antigen presenting cells. Journal of Immunotherapy 43(3):79−88

Zhang Q, Wei W, Wang P, Zuo L, Li F, et al. 2017. Biomimetic magnetosomes as versatile artificial antigen-presenting cells to potentiate T-cell-based anticancer therapy. ACS Nano 11(11):10724−10732

Li SY, Liu Y, Xu CF, Shen S, Sun R, et al. 2016. Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation. Journal of Controlled Release 231:17−28

Demento SL, Cui W, Criscione JM, Stern E, Tulipan J, et al. 2012. Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. Biomaterials 33(19):4957−4964

Emami Nejad A, Najafgholian S, Rostami A, Sistani A, Shojaeifar S, et al. 2021. The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell International 21(1):62

Estrella V, Chen T, Lloyd M, Wojtkowiak J, Cornnell HH, et al. 2013. Acidity generated by the tumor microenvironment drives local invasion. Cancer Research 73(5):1524−1535

Wan D, Song Y, Lu X, Huang Y, Zhang J, et al. 2024. Nanoscale "precision strike": tumor microenvironment-responsive smart micelles for efficient targeted drug delivery. Nano Research 17(9):8360−8367

Srinivasarao DA, Shah S, Famta P, Vambhurkar G, Jain N, et al. 2025. Unravelling the role of tumor microenvironment responsive nanobiomaterials in spatiotemporal controlled drug delivery for lung cancer therapy. Drug Delivery and Translational Research 15(2):407−435

Chen Y, Ma H, Wang W, Zhang M. 2021. A size-tunable nanoplatform: enhanced MMP2-activated chemo-photodynamic immunotherapy based on biodegradable mesoporous silica nanoparticles. Biomaterials Science 9(3):917−929

Wang D, Wang T, Yu H, Feng B, Zhou L, et al. 2019. Engineering nanoparticles to locally activate T cells in the tumor microenvironment. Science Immunology 4(37):eaau6584

Xian S, Chen X, Ren S, Chen X, Wang H. 2024. Ionizable STING-activating nanoadjuvants enhance tumor immunogenicity and potentiate immunotherapy efficacy in solid tumors. Cancer Research 84(18):3044−3057

Ritu, Chandra P, Das A. 2023. Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics. Clinical and Experimental Medicine 23(8):4297−4322

Feng L, Dong Z, Tao D, Zhang Y, Liu Z. 2018. The acidic tumor microenvironment: a target for smart cancer nano-theranostics. National Science Review 5(2):269−286

Qin J, Zhu Y, Zheng D, Zhao Q. 2021. pH-sensitive polymeric nanocarriers for antitumor biotherapeutic molecules targeting delivery. Bio-Design and Manufacturing 4(3):612−626

Bulbake U, Doppalapudi S, Kommineni N, Khan W. 2017. Liposomal formulations in clinical use: an updated review. Pharmaceutics 9(2):12

Tornesello AL, Tagliamonte M, Tornesello ML, Buonaguro FM, Buonaguro L. 2020. Nanoparticles to improve the efficacy of peptide-based cancer vaccines. Cancers 12(4):1049

Kulkarni JA, Cullis PR, van der Meel R. 2018. Lipid nanoparticles enabling gene therapies: from concepts to clinical utility. Nucleic Acid Therapeutics 28(3):146−157

Woodman C, Vundu G, George A, Wilson CM. 2021. Applications and strategies in nanodiagnosis and nanotherapy in lung cancer. Seminars in Cancer Biology 69:349−364

Martin JD, Cabral H, Stylianopoulos T, Jain RK. 2020. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nature Reviews Clinical Oncology 17(4):251−266

Goldberg MS. 2019. Improving cancer immunotherapy through nanotechnology. Nature Reviews Cancer 19(10):587−602

Lee KW, Jeong D, Na K. 2013. Doxorubicin loading fucoidan acetate nanoparticles for immune and chemotherapy in cancer treatment. Carbohydrate Polymers 94(2):850−856

Gurung S, Khan F, Gunassekaran GR, Do Yoo J, Poongkavithai Vadevoo SM, et al. 2020. Phage display-identified PD-L1-binding peptides reinvigorate T-cell activity and inhibit tumor progression. Biomaterials 247:119984

Boland JL, Zhou Q, Martin M, Callahan MK, Konner J, et al. 2019. Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade. Gynecologic Oncology 152(2):251−258

Sharpe AH, Pauken KE. 2018. The diverse functions of the PD1 inhibitory pathway. Nature Reviews Immunology 18(3):153−167

Zang X, Zhao X, Hu H, Qiao M, Deng Y, et al. 2017. Nanoparticles for tumor immunotherapy. European Journal of Pharmaceutics and Biopharmaceutics 115:243−256

Paulis LE, Mandal S, Kreutz M, Figdor CG. 2013. Dendritic cell-based nanovaccines for cancer immunotherapy. Current Opinion in Immunology 25(3):389−395

Shao K, Singha S, Clemente-Casares X, Tsai S, Yang Y, et al. 2015. Nanoparticle-based immunotherapy for cancer. ACS Nano 9(1):16−30

Guo Y, Wang D, Song Q, Wu T, Zhuang X, et al. 2015. Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for induction of antitumor immunity against melanoma. ACS Nano 9:6918−6933

Perica K, De León Medero A, Durai M, Chiu YL, Bieler JG, et al. 2014. Nanoscale artificial antigen presenting cells for T cell immunotherapy. Nanomedicine: Nanotechnology, Biology and Medicine 10(1):119−129

Nawaz W, Xu S, Li Y, Huang B, Wu X, et al. 2020. Nanotechnology and immunoengineering: how nanotechnology can boost CAR-T therapy. Acta Biomaterialia 109:21−36

Khawar MB, Afzal A, Abbasi MH, Sheikh N, Sun H. 2023. Nano-immunoengineering of CAR-T cell therapy against tumor microenvironment: the way forward in combating cancer. OpenNano 10:100124

Nguyen NT, Huang K, Zeng H, Jing J, Wang R, et al. 2021. Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety. Nature Nanotechnology 16(12):1424−1434

Miliotou AN, Papadopoulou LC. 2018. CAR T-cell therapy: a new era in cancer immunotherapy. Current Pharmaceutical Biotechnology 19(1):5−18

Zeng Q, Liu Z, Niu T, He C, Qu Y, et al. 2023. Application of nanotechnology in CAR-T-cell immunotherapy. Chinese Chemical Letters 34(3):107747

Fu R, Li H, Li R, McGrath K, Dotti G, et al. 2021. Delivery techniques for enhancing CAR T cell therapy against solid tumors. Advanced Functional Materials 31(44):2009489

Tao B, Du R, Zhang X, Jia B, Gao Y, et al. 2023. Engineering CAR-NK cell derived exosome disguised nano-bombs for enhanced HER2 positive breast cancer brain metastasis therapy. Journal of Controlled Release 363:692−706

Baghery Saghchy Khorasani A, Yousefi AM, Bashash D. 2022. CAR NK cell therapy in hematologic malignancies and solid tumors; obstacles and strategies to overcome the challenges. International Immunopharmacology 110:109041

Kim KS, Han JH, Park JH, Kim HK, Choi SH, et al. 2019. Multifunctional nanoparticles for genetic engineering and bioimaging of natural killer (NK) cell therapeutics. Biomaterials 221:119418

Varghese RJ, Sakho EHM, Parani S, Thomas S, Oluwafemi OS, et al. 2019. Introduction to nanomaterials: synthesis and applications. In Nanomaterials for Solar Cell Applications. Amsterdam: Elsevier. pp. 75−95 doi: 10.1016/b978-0-12-813337-8.00003-5

Harish V, Ansari MM, Tewari D, Gaur M, Yadav AB, et al. 2022. Nanoparticle and nanostructure synthesis and controlled growth methods. Nanomaterials 12(18):3226

Saleh TA. 2020. Nanomaterials: classification, properties, and environmental toxicities. Environmental Technology & Innovation 20:101067

Mirzayans R, Murray D. 2023. Intratumor heterogeneity and treatment resistance of solid tumors with a focus on polyploid/senescent giant cancer cells (PGCCs). International Journal of Molecular Sciences 24(14):11534

Xu Q, Lan X, Lin H, Xi Q, Wang M, et al. 2023. Tumor microenvironment-regulating nanomedicine design to fight multi-drug resistant tumors. WIREs Nanomedicine and Nanobiotechnology 15:e1842

Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, et al. 2014. Drug resistance in cancer: an overview. Cancers 6(3):1769−1792

Zhang Q, Feng Y, Kennedy D. 2017. Multidrug-resistant cancer cells and cancer stem cells hijack cellular systems to circumvent systemic therapies, can natural products reverse this? Cellular and Molecular Life Sciences 74(5):777−801

Davodabadi F, Sajjadi SF, Sarhadi M, Mirghasemi S, Nadali Hezaveh M, et al. 2023. Cancer chemotherapy resistance: mechanisms and recent breakthrough in targeted drug delivery. European Journal of Pharmacology 958:176013

Cruz E, Kayser V. 2019. Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy. Biologics: Targets and Therapy 13:33−51

Yoo H, Kim Y, Kim J, Cho H, Kim K. 2024. Overcoming cancer drug resistance with nanoparticle strategies for key protein inhibition. Molecules 29(17):3994

Yang C, Ding Y, Mao Z, Wang W. 2024. Nanoplatform-mediated autophagy regulation and combined anti-tumor therapy for resistant tumors. International Journal of Nanomedicine 19:917−944

He S, Gou X, Zhang S, Zhang X, Huang H, et al. 2024. Nanodelivery systems as a novel strategy to overcome treatment failure of cancer. Small Methods 8(1):2301127

Ashique S, Garg A, Hussain A, Farid A, Kumar P, et al. 2023. Nanodelivery systems: an efficient and target-specific approach for drug-resistant cancers. Cancer Medicine 12(18):18797−18825

Maimaitijiang A, He D, Li D, Li W, Su Z, et al. 2024. Progress in research of nanotherapeutics for overcoming multidrug resistance in cancer. International Journal of Molecular Sciences 25(18):9973

Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, et al. 2016. Analysis of nanoparticle delivery to tumours. Nature Reviews Materials 1:16014

Reya T, Morrison SJ, Clarke MF, Weissman IL. 2001. Stem cells, cancer, and cancer stem cells. Nature 414(6859):105−111

Miyata K, Christie RJ, Kataoka K. 2011. Polymeric micelles for nano-scale drug delivery. Reactive and Functional Polymers 71(3):227−234

Xu W, Ling P, Zhang T. 2013. Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs. Journal of Drug Delivery 2013(1):340315

Sztandera K, Gorzkiewicz M, Klajnert-Maculewicz B. 2019. Gold nanoparticles in cancer treatment. Molecular Pharmaceutics 16(1):1−23

Cai W, Gao T, Hong H, Sun J. 2008. Applications of gold nanoparticles in cancer nanotechnology. Nanotechnology, Science and Applications 1:17−32

England CG, Gobin AM, Frieboes HB. 2015. Evaluation of uptake and distribution of gold nanoparticles in solid tumors. The European Physical Journal Plus 130(11):231

Paciotti GF, Kingston DGI, Tamarkin L. 2006. Colloidal gold nanoparticles: a novel nanoparticle platform for developing multifunctional tumor-targeted drug delivery vectors. Drug Development Research 67(1):47−54

Izci M, Maksoudian C, Gonçalves F, Aversa L, Salembier R, et al. 2022. Gold nanoparticle delivery to solid tumors: a multiparametric study on particle size and the tumor microenvironment. Journal of Nanobiotechnology 20(1):518

Dendrou CA, Fugger L, Friese MA. 2015. Immunopathology of multiple sclerosis. Nature Reviews Immunology 15(9):545−558

Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, et al. 2016. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534(7607):396−401

Reddy ST, van der Vlies AJ, Simeoni E, Angeli V, Randolph GJ, et al. 2007. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nature Biotechnology 25(10):1159−1164

Purcell BP, Lobb D, Charati MB, Dorsey SM, Wade RJ, et al. 2014. Injectable and bioresponsive hydrogels for on-demand matrix metalloproteinase inhibition. Nature Materials 13(6):653−661

Moon JJ, Suh H, Bershteyn A, Stephan MT, Liu H, et al. 2011. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nature Materials 10(3):243−251

Lynn GM, Laga R, Darrah PA, Ishizuka AS, Balaci AJ, et al. 2015. In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. Nature Biotechnology 33(11):1201−1210

Hani U, Jaswanth Gowda BH, Haider N, Ramesh K, Paul K, et al. 2023. Nanoparticle-based approaches for treatment of hematological malignancies: a comprehensive review. AAPS PharmSciTech 24(8):233

Samal P, Begum S. 2022. Drug loaded nanomaterials for hematological malignancies diagnosis and enhanced targeted therapy. In Advanced Nanomaterials for Point of Care Diagnosis and Therapy. Amsterdam: Elsevier. pp. 383−398 doi: 10.1016/b978-0-323-85725-3.00016-7

Deshantri AK, Varela Moreira A, Ecker V, Mandhane SN, Schiffelers RM, et al. 2018. Nanomedicines for the treatment of hematological malignancies. Journal of Controlled Release 287:194−215

Weber AL, Rahemtullah A, Ferry JA. 2003. Hodgkin and non-Hodgkin lymphoma of the head and neck Clinical, pathologic, and imaging evaluation. Neuroimaging Clinics of North America 13(3):371−392

Shanbhag S, Ambinder RF. 2018. Hodgkin lymphoma: a review and update on recent progress. CA: A Cancer Journal for Clinicians 68(2):116−132

Visani G, Isidori A. 2011. Doxorubicin variants for hematological malignancies. Nanomedicine 6(2):303−306

Tuscano JM, Martin SM, Ma Y, Zamboni W, O'Donnell RT. 2010. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model. Clinical Cancer Research 16(10):2760−2768

Ashley JD, Quinlan CJ, Schroeder VA, Suckow MA, Pizzuti VJ, et al. 2016. Dual carfilzomib and doxorubicin–loaded liposomal nanoparticles for synergistic efficacy in multiple myeloma. Molecular Cancer Therapeutics 15(7):1452−1459

Russo D, Piccaluga P, Michieli M, Michelutti T, Visani G, et al. 2002. Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia. Annals of Hematology 81(8):462−466

Davis T, Farag SS. 2013. Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine. International Journal of Nanomedicine 8:3479−3488

Raj TAS, Smith AM, Moore AS. 2013. Vincristine sulfate liposomal injection for acute lymphoblastic leukemia. International Journal of Nanomedicine 8:4361−4369

Rivera D, Kadia TM, Montalban-Bravo G, Faderl S, Sasaki K, et al. 2021. Liposomal cytarabine and daunorubicin (CPX-351) in combination with gemtuzumab ozogamicin (GO) in relapsed refractory (R/R) acute myeloid leukemia (AML) and post-hypomethylating agent (post-HMA) failure high-risk myelodysplastic syndrome (HR-MDS). Blood 138:2323

Dong Y, Wu X, Chen X, Zhou P, Xu F, et al. 2021. Nanotechnology shaping stem cell therapy: recent advances, application, challenges, and future outlook. Biomedicine & Pharmacotherapy 137:111236

Yi DK, Nanda SS, Kim K, Tamil Selvan S. 2017. Recent progress in nanotechnology for stem cell differentiation, labeling, tracking and therapy. Journal of Materials Chemistry B 5(48):9429−9451

Habibi S, Khamisipour GH, Obeidi N, Zare Jaliseh S. 2020. Direct differentiation of human primary fibroblast into hematopoietic-like stem cells. Cell Journal 22:141−147

Marano F, Hussain S, Rodrigues-Lima F, Baeza-Squiban A, Boland S. 2011. Nanoparticles: molecular targets and cell signalling. Archives of Toxicology 85(7):733−741

Huang L, Huang J, Huang J, Xue H, Liang Z, et al. 2020. Nanomedicine–a promising therapy for hematological malignancies. Biomaterials Science 8(9):2376−2393

Dorrance AM, Neviani P, Ferenchak GJ, Huang X, Nicolet D, et al. 2015. Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia. Leukemia 29(11):2143−2153

Johnson DT, Zhou J, Kroll AV, Fang RH, Yan M, et al. 2022. Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy. Leukemia 36(4):994−1005

Chen F, Shi Y, Zhang J, Liu Q. 2020. Nanoparticle-based drug delivery systems for targeted epigenetics cancer therapy. Current Drug Targets 21(11):1084−1098

Su FY, Chuang EY, Lin PY, Chou YC, Chen CT, et al. 2014. Treatment of chemotherapy-induced neutropenia in a rat model by using multiple daily doses of oral administration of G-CSF-containing nanoparticles. Biomaterials 35(11):3641−3649

Hazan-Halevy I, Landesman-Milo D, Rosenblum D, Mizrahy S, Ng BD, et al. 2016. Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines. Journal of Controlled Release 244:149−156

Ghosh S, Lalani R, Patel V, Bardoliwala D, Maiti K, et al. 2019. Combinatorial nanocarriers against drug resistance in hematological cancers: opportunities and emerging strategies. Journal of Controlled Release 296:114−139

Zhang R, Billingsley MM, Mitchell MJ. 2018. Biomaterials for vaccine-based cancer immunotherapy. Journal of Controlled Release 292:256−276

Thomas SN, Vokali E, Lund AW, Hubbell JA, Swartz MA. 2014. Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. Biomaterials 35(2):814−824

Caster JM, Wang AZ. 2017. Applying nanotherapeutics to improve chemoradiotherapy treatment for cancer. Therapeutic Delivery 8(9):791−803

Gavas S, Quazi S, Karpiński TM. 2021. Nanoparticles for cancer therapy: current progress and challenges. Nanoscale Research Letters 16(1):173

Prajapati A, Rangra S, Patil R, Desai N, Jyothi VGSS, et al. 2024. Receptor-targeted nanomedicine for cancer therapy. Receptors 3(3):323−361

Sun Y. 2016. Tumor microenvironment and cancer therapy resistance. Cancer Letters 380(1):205−215

Yang S, Gao H. 2017. Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy. Pharmacological Research 126:97−108

Taylor S, Spugnini EP, Assaraf YG, Azzarito T, Rauch C, et al. 2015. Microenvironment acidity as a major determinant of tumor chemoresistance: proton pump inhibitors (PPIs) as a novel therapeutic approach. Drug Resistance Updates 23:69−78

Aslan B, Ozpolat B, Sood AK, Lopez-Berestein G. 2013. Nanotechnology in cancer therapy. Journal of Drug Targeting 21(10):904−913

Arafat M, Sakkal M, Beiram R, AbuRuz S. 2024. Nanomedicines: emerging platforms in smart chemotherapy treatment—a recent review. Pharmaceuticals 17(3):315

Abu Dayyih W, Hailat M, Albtoush S, Albtoush E, Abu Dayah A, et al. 2024. Nanomedicine advancements in cancer therapy: a scientific review. Jordan Journal of Pharmaceutical Sciences 17(3):506−529

Al Refaai KA, AlSawaftah NA, Abuwatfa W, Husseini GA. 2024. Drug release via ultrasound-activated nanocarriers for cancer treatment: a review. Pharmaceutics 16(11):1383

Chaudhari NS, Pandey AP, Patil PO, Tekade AR, Bari SB, et al. 2014. Graphene oxide based magnetic nanocomposites for efficient treatment of breast cancer. Materials Science and Engineering: C 37:278−285

Guo R, Zhang L, Qian H, Li R, Jiang X, et al. 2010. Multifunctional nanocarriers for cell imaging, drug delivery, and near-IR photothermal therapy. Langmuir 26(8):5428−5434

Wu YL, Yin H, Zhao F, Li J. 2013. Multifunctional hybrid nanocarriers consisting of supramolecular polymers and quantum dots for simultaneous dual therapeutics delivery and cellular imaging. Advanced Healthcare Materials 2(2):297−301

Xu J. 2019. Multifunctional nanocarriers for combination cancer therapy. Thesis. University of Pittsburgh, USA

Nel AE, Mei KC, Liao YP, Liu X. 2022. Multifunctional lipid bilayer nanocarriers for cancer immunotherapy in heterogeneous tumor microenvironments, combining immunogenic cell death stimuli with immune modulatory drugs. ACS Nano 16(4):5184−5232

Ju Y, Kim CJ, Caruso F. 2023. Functional ligand-enabled particle assembly for bio–nano interactions. Accounts of Chemical Research 56(13):1826−1837

Loganathan P, Magzoub M. 2023. Peptide functionalized nanocarriers for targeted drug delivery in cancer therapy. Biophysical Journal 122(3):291a

Kumar R, Dkhar DS, Kumari R, Divya, Mahapatra S, et al. 2022. Ligand conjugated lipid-based nanocarriers for cancer theranostics. Biotechnology and Bioengineering 119(11):3022−3043

Wang H, Ouyang W, Liu H. 2024. Tumor microenvironment responsive nanozymes for multimodal imaging of tumors. Nano TransMed 3:100032

Zhu M, Ren G, Guo J, Chen X, Long R, et al. 2024. Hypoxia-responsive nanomicelle based on 2-nitroimidazole for tumor treatment through chemotherapy and modulation of the tumor redox microenvironment. ACS Applied Nano Materials 7(11):12452−12465

Garello F, Cavallari E, Capozza M, Ribodino M, Parolisi R, et al. 2025. MRI detection of free-contrast agent nanoparticles. Magnetic Resonance in Medicine 93(2):761−774

Wang Y, Sun Z, Chen Z, Wu Y, Gu Y, et al. 2019. In vivo photoacoustic/single-photon emission computed tomography imaging for dynamic monitoring of aggregation-enhanced photothermal nanoagents. Analytical Chemistry 91(3):2128−2134

Rouchota M, Adamiano A, Iafisco M, Fragogeorgi E, Pilatis I, et al. 2021. Optimization of in vivo studies by combining planar dynamic and tomographic imaging: workflow evaluation on a superparamagnetic nanoparticles system. Molecular Imaging 2021:6677847

Fan L, Yang J, Leung KC, Song C, Li Q. 2018. Noninvasive real-time monitoring of local drug release using nano-Au-absorbed self-decomposable SiO₂ carriers. Nanoscale 10(32):15332−15338

Barenholz Y. 2012. Doxil®—The first FDA-approved nano-drug: lessons learned. Journal of Controlled Release 160(2):117−134

Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, et al. 2013. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New England Journal of Medicine 369(18):1691−1703

Desai N, Trieu V, Yao Z, Louie L, Ci S, et al. 2006. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clinical Cancer Research 12(4):1317−1324

Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, et al. 2021. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. The Lancet Haematology 8(7):e481−e491

Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, et al. 2018. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine 379(1):11−21

Autio KA, Dreicer R, Anderson J, Garcia JA, Alva A, et al. 2018. Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: a phase 2 clinical trial. JAMA Oncology 4(10):1344

Miller K, Cortes J, Hurvitz SA, Krop IE, Tripathy D, et al. 2016. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. BMC Cancer 16(1):352

Santos MA. 2020. Towards overcoming limitations on MRI-guided focused ultrasound hyperthermia-mediated drug delivery using thermosensitive liposomes. Thesis. University of Toronto, Canada

Zuckerman JE, Davis ME. 2015. Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nature Reviews Drug Discovery 14(12):843−856

Amani A, Begdelo JM, Yaghoubi H, Motallebinia S. 2019. Multifunctional magnetic nanoparticles for controlled release of anticancer drug, breast cancer cell targeting, MRI/fluorescence imaging, and anticancer drug delivery. Journal of Drug Delivery Science and Technology 49:534−546

Chen JS, Chen J, Bhattacharjee S, Cao Z, Wang H, et al. 2020. Functionalized nanoparticles with targeted antibody to enhance imaging of breast cancer in vivo. Journal of Nanobiotechnology 18(1):135

Xu J, Li R, Yan D, Zhu L. 2024. Biomimetic modification of siRNA/chemo drug nanoassemblies for targeted combination therapy in breast cancer. ACS Applied Materials & Interfaces 16(44):59765−59776

Pourali P, Neuhöferová E, Dzmitruk V, Svoboda M, Stodůlková E, et al. 2024. Bioproduced nanoparticles deliver multiple cargoes via targeted tumor therapy in vivo. ACS Omega 9(31):33789−33804

Kim T, Han HS, Yang K, Kim YM, Nam K, et al. 2024. Nanoengineered polymeric RNA nanoparticles for controlled biodistribution and efficient targeted cancer therapy. ACS Nano 18(11):7972−7988

Abbasi Dezfouli S, Rajendran AP, Claerhout J, Uludag H. 2023. Designing nanomedicines for breast cancer therapy. Biomolecules 13(10):1559

Wang J, Zhu X, Jiang H, Ji M, Wu Y, et al. 2024. Cancer cell-derived exosome based dual-targeted drug delivery system for non-small cell lung cancer therapy. Colloids and Surfaces B: Biointerfaces 244:114141

He ZH, Qi LJ, He XY, Han D, Liao XR, et al. 2024. Enhancing targeted cancer therapy through multiple drug delivery by silk peptide nanoparticles. Nano Select 5(5):2300176

Zhou J, Wan S, Wu Y, Hu H, Liu Y, et al. 2024. Cancer cell membrane-camouflaged paclitaxel/PLGA nanoparticles for targeted therapy against lung cancer. Biomedicine & Pharmacotherapy 177:117102

Abdel-Hafez SM, Gallei M, Wagner S, Schneider M. 2024. Inhalable nano-structured microparticles for extracellular matrix modulation as a potential delivery system for lung cancer. European Journal of Pharmaceutics and Biopharmaceutics 204:114512

Ali Taheri R, Fathi H, Sharafi A, Mirzaei M, Jafari S, et al. 2024. Niosomes loaded with gold nanoparticles for enhanced radiation therapy in lung cancer. Nanomedicine 19(27):2257−2270

Wang Z, Xing H, Liu A, Guan L, Li X, et al. 2023. Multifunctional nano-system for multi-mode targeted imaging and enhanced photothermal therapy of metastatic prostate cancer. Acta Biomaterialia 166:581−592

Wang Z, Liu A, Li X, Guan L, Xing H, et al. 2023. Multifunctional nanoprobe for multi-mode imaging and diagnosis of metastatic prostate cancer. Talanta 256:124255

Hasan M, Pathan MKM, Kabir MF. 2024. Functionalized mesoporous silica nanoparticles as potential drug delivery vehicle against colorectal cancer. Journal of Medical and Health Studies 5(3):56−62

Kadyr S, Zhuraliyeva A, Yermekova A, Makhambetova A, Kaldybekov DB, et al. 2024. PLGA-PEG nanoparticles loaded with Cdc42 inhibitor for colorectal cancer targeted therapy. Pharmaceutics 16(10):1301

Liu R, Miao Y, Wen K, Yang Y, Xu D, et al. 2024. Salmonella Biomimetic nanoparticles for photothermal-chemotherapy of colorectal cancer. Nano Letters 24(43):13851−13860

Li Y, Chen J, Xia Q, Shang J, He Y, et al. 2024. Photothermal Fe₃O₄ nanoparticles induced immunogenic ferroptosis for synergistic colorectal cancer therapy. Journal of Nanobiotechnology 22(1):630

Mann RA, Hossen ME, Withrow ADM, Burton JT, Blythe SM, et al. 2024. Mesoporous silica nanoparticles-based smart nanocarriers for targeted drug delivery in colorectal cancer therapy. arXiv Preprint:2409.18809

Sun R, Chen Y, Pei Y, Wang W, Zhu Z, et al. 2024. The drug release of PLGA-based nanoparticles and their application in treatment of gastrointestinal cancers. Heliyon 10(18):e38165

Huang HL, Chen KW, Liao HW, Wang LY, Peng SL, et al. 2024. Nanoparticles for augmenting therapeutic potential and alleviating the effect of di(2-ethylhexyl) phthalate on gastric cancer. ACS Applied Materials & Interfaces 16(15):18285−18299

Lin X, Huang M, Chen J, Zhou X, Zhong Z, et al. 2023. Manganese-based nanoparticles for chemodynamic therapy of gastrointestinal cancer. Nan Fang Yi Ke Da Xue Xue Bao 43(8):1432−1439 (in Chinese)

Huang HL, Lai CH, Tsai WH, Chen KW, Peng SL, et al. 2024. Nanoparticle-enhanced postbiotics: revolutionizing cancer therapy through effective delivery. Life Sciences 337:122379

Martins A, Ferreira BC, Gaspar M, Vieira S, Lopes J, et al. 2024. 1114: Potential of concomitant radiation therapy with gold nanoparticles for pancreatic cancer. Radiotherapy and Oncology 194:S5369−S5371

Nakayama M, Noda A, Akasaka H, Tominaga T, McCorkell G, et al. 2024. Ultrasound-stimulated microbubbles for treatment of pancreatic cancer cells with radiation and nanoparticles: in vitro study. Journal of Medical Physics 49(3):326−334

Martins A, Ferreira BC, Gaspar MM, Vieira S, Lopes J, et al. 2024. Enhanced cytotoxicity against a pancreatic cancer cell line combining radiation and gold nanoparticles. Pharmaceutics 16(7):900

Nedelcu A, Mocan T, Sabau LI, Matea CT, Tabaran F, et al. 2024. In vitro photothermal therapy of pancreatic cancer mediated by immunoglobulin G-functionalized silver nanoparticles. Scientific Reports 14:14417

Sugo Y, Kimura A, Koizumi T, Oyama K, Taguchi M. 2024. Development of gelatin nanoparticles for positron emission tomography diagnosis in pancreatic cancer. Radiochimica Acta 112(12):971−980

Spadea A, Tirella A, Rios de la Rosa JM, Lallana E, Mehibel M, et al. 2024. Targeting hypoxia-inducible factor-1α in pancreatic cancer: siRNA delivery using hyaluronic acid-displaying nanoparticles. Pharmaceutics 16(10):1286

Rehman U, Parveen N, Sheikh A, Abourehab MAS, Sahebkar A, et al. 2022. Polymeric nanoparticles-siRNA as an emerging nano-polyplexes against ovarian cancer. Colloids and Surfaces B: Biointerfaces 218:112766

Guo C, Cheng X, Yang Y, Wang L, Wang W, et al. 2025. Aptamer-modified GSH-degradable honokiol polyprodrug nanoparticles for ovarian cancer-specific targeting therapy. Bioorganic & Medicinal Chemistry Letters 123:130215

Ye M, Ye R, Wang Y, Guo M, Zhu M, et al. 2024. Targeted pH-responsive biomimetic nanoparticle-mediated starvation-enhanced chemodynamic therapy combined with chemotherapy for ovarian cancer treatment. International Journal of Pharmaceutics 661:124426

Li G, Shi S, Tan J, He L, Liu Q, et al. 2024. Highly efficient synergistic chemotherapy and magnetic resonance imaging for targeted ovarian cancer therapy using hyaluronic acid-coated coordination polymer nanoparticles. Advanced Science 11(41):2309464

Tunki L, Kulhari H, Vadithe LN, Kuncha M, Bhargava S, et al. 2019. Modulating the site-specific oral delivery of sorafenib using sugar-grafted nanoparticles for hepatocellular carcinoma treatment. European Journal of Pharmaceutical Sciences 137:104978

Yu N, Su M, Wang J, Liu Y, Yang J, et al. 2024. Long-term exposure of fresh and aged nano zinc oxide promotes hepatocellular carcinoma malignancy by up-regulating claudin-2. International Journal of Nanomedicine 19:9989−10008

Gharibkandi NA, Wawrowicz K, Walczak R, Majkowska-Pilip A, Wierzbicki M, et al. 2024. ¹⁰⁹Pd/^109mAg in-vivo generator in the form of nanoparticles for combined β⁻-Auger electron therapy of hepatocellular carcinoma. EJNMMI Radiopharmacy and Chemistry 9(1):59

Chen H, Liu J, Cao Z, Li J, Zhang H, et al. 2025. Enhancing hepatocellular carcinoma therapy with DOX-loaded SiO₂ nanoparticles via mTOR-TFEB pathway autophagic flux inhibition. Journal of Nanobiotechnology 23(1):27

Yang X, Zhang Q, Li D, Hu L, Wang Y, et al. 2024. A multifunctional nanodrug increases the therapeutic sensitivity of lenvatinib to hepatocellular carcinoma by inhibiting the stemness of hepatic cancer stem cells. Advanced Healthcare Materials 13(29):2401398

Fawaz W, Hanano A, Murad H, Yousfan A, Alghoraibi I, et al. 2024. Polymeric nanoparticles loaded with vincristine and carbon dots for hepatocellular carcinoma therapy and imaging. Scientific Reports 14:24520

Du B, Chong Y, Jiang X, Yu M, Lo UG, et al. 2021. Hyperfluorescence imaging of kidney cancer enabled by renal secretion pathway dependent efflux transport. Angewandte Chemie International Edition 60(1):351−359

Dai T, Wang Q, Zhu L, Luo Q, Yang J, et al. 2024. Combined UTMD-nanoplatform for the effective delivery of drugs to treat renal cell carcinoma. International Journal of Nanomedicine 19:8519−8540

Ferreira LAB, Garcia-Fossa F, Radaic A, Durán N, Fávaro WJ, et al. 2020. Biogenic silver nanoparticles: in vitro and in vivo antitumor activity in bladder cancer. European Journal of Pharmaceutics and Biopharmaceutics 151:162−170

Wang B, Zhang K, Wang J, Zhao R, Zhang Q, et al. 2020. Poly(amidoamine)-modified mesoporous silica nanoparticles as a mucoadhesive drug delivery system for potential bladder cancer therapy. Colloids and Surfaces B: Biointerfaces 189:110832

Wu Z, Li B, Qie Y, Wu S, Qi F, et al. 2024. Targeted inhibition of lymphovascular invasion formation with CREKA peptide-modified silicasomes to boost chemotherapy in bladder cancer. Nano Letters 24(33):10186−10195

Liu F, Guo C, Li X, Li Y, Xu S, et al. 2024. A versatile nano-transformer for efficient localization-specific imaging and synergistic therapy of bladder cancer. Nano Today 54:102116

Li Y, Shan S, Zhang R, Sun C, Hu X, et al. 2024. Imaging and downstaging bladder cancer with the ¹⁷⁷Lu-labeled bioorthogonal nanoprobe. ACS Nano 18(26):17209−17217

Wang P, Wei X, Shen L, Xu K, Wen Z, et al. 2024. Amplification-free analysis of bladder cancer microRNAs on wrinkled silica nanoparticles with DNA-functionalized quantum dots. Analytical Chemistry 96(12):4860−4867

Gdowski A, Kim L, Lai X, Ma X, Raupp J, et al. 2024. Pre-clinical safety and efficacy evaluation of sodium chloride nanoparticles for treating non-muscle invasive bladder cancer. Journal of Clinical Oncology 42(16):e14591

Yang J, Liu B, Wang Q, Yan H, Li G, et al. 2024. Carboxylated mesoporous silica nanoparticle-nucleic acid Chimera conjugate-assisted delivery of siRNA and doxorubicin effectively treat drug-resistant bladder cancer. Biomedicine & Pharmacotherapy 178:117185

Pereira Santos Carvalho I, Bueno Silva L, Luis Ferraz do Amaral R, Nader Chrysostomo-Massaro T, Dias de Lima Fragelli B, et al. 2024. Evaluation of in vivo and in vitro efficacy of solasonine/solamargine-loaded lipid-polymer hybrid nanoparticles against bladder cancer. International Journal of Pharmaceutics 661:124411